Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

RIG-I activating immunostimulatory RNA boosts the efficacy of anticancer vaccines and synergizes with immune checkpoint blockade

1 Mar 2019

Abstract excerpt

BACKGROUND: Antibody-mediated targeting of regulatory T cell receptors such as CTLA-4 enhances antitumor immune responses against several cancer entities including malignant melanoma. Yet, therapeutic success in patients remains variable underscoring the need for novel combinatorial approaches. METHODS: Here we established a vaccination strategy that combines engagement of the nucleic acid-sensing pattern...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to Immunotherapy and Immune Responses
Share to interferon and immune responses

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30852164
DOI: 10.1016/j.ebiom.2019.02.056

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

RIG-I activating immunostimulatory RNA boosts the efficacy of anticancer vaccines and synergizes with immune checkpoint blockadePMID 30852164Read ↗

RIG-I immunotherapy overcomes radioresistance in p53-positive malignant melanomaSemantic proximity Read ↗

A Nanoparticle RIG-I Agonist for Cancer ImmunotherapySemantic proximity Read ↗

RIG-I is an intracellular checkpoint that limits CD8+ T-cell antitumor immunitySemantic proximity Read ↗

The Innate Immune Signalling Pathways: Turning RIG-I Sensor Activation against CancerSemantic proximity Read ↗

RIG-I RNA agonist activates immunostimulatory macrophages to enhance checkpoint immunotherapy for glioblastomaSemantic proximity Read ↗

Tumor cell intrinsic RIG-I activation co-opts the host microenvironment to drive immune mediated tumor rejectionSemantic proximity Read ↗

CDK4/6 inhibition and dsRNA sensor agonism co-operate to enhance anti-cancer effects through ER stress and immune modulation of tumour cellsSemantic proximity Read ↗

A modified oncolytic measles virus exhibits strong immunotherapeutic potential through RIG-I activation by defective viral genomesSemantic proximity Read ↗

Reprogramming the anti-tumor immune response via CRISPR genetic and epigenetic editingSemantic proximity Read ↗

RIG-I Stimulation Enhances Effector Function and Proliferation of Primary Human CD8 T CellsSemantic proximity Read ↗

IPS-1 differentially induces TRAIL, BCL2, BIRC3 and PRKCE in type I interferons-dependent and -independent anticancer activitySemantic proximity Read ↗

Disabling a key viral innate immunity antagonist converts measles vaccine into RIG-I–driven cancer immunotherapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.